Industry Insights - The global weight loss drug market is projected to reach approximately $130 billion by 2034, with a compound annual growth rate (CAGR) of 13%-15% from 2024 to 2034, driven by a low penetration rate of about 1% among the over 900 million obese individuals worldwide [2][5] - The clinical advantages of tirzepatide, a dual receptor agonist, have led to a significant market share, capturing 67% of new prescriptions and 63% of total prescriptions in the U.S. by October 2025 [2][5] - The expansion of insurance coverage and decreasing drug prices in the U.S. are expected to catalyze demand, with Medicare Part D now covering weight loss treatments for patients with comorbidities [5] Technological Advancements - The development of weight loss drugs is focusing on four key areas: long-acting formulations, oral administration, enhanced efficacy, and muscle preservation during weight loss [6] - Notable advancements include Pfizer's monthly GLP-1 and insulin formulations, and oral small molecule GLP-1 receptor agonists from companies like Eli Lilly and Mondelēz [6][7] Company Analysis - The report highlights the potential of Gako's JAB-23E73 (pan-KRAS) as a groundbreaking drug, showing promising early efficacy and safety compared to competitors [8][9] - JAB-23E73 has demonstrated a treatment-related adverse event rate of 11.9%, significantly lower than the 34% observed with RMC-6236, indicating a favorable safety profile [9] - Gako's financial position is robust, with a cash balance of 1.13 billion RMB and expected revenue from partnerships, positioning the company well for future growth [11]

Core Viewpoint - Morgan Stanley expresses that the inclusion of Eli Lilly's Tirzepatide in the national medical insurance directory is not entirely surprising and believes that Innovent Biologics (01801) can adopt flexible pricing strategies to respond to market changes [1] Group 1: Market Potential and Product Pipeline - The Chinese weight loss drug market is vast, providing ample space for the development of multiple blockbuster drugs [1] - Innovent Biologics is rated "Overweight" due to its product pipeline covering various fields including oncology, autoimmune diseases, metabolic diseases, and ophthalmology [1] - Short to medium-term investors may focus on the company's ability to license assets externally [1] Group 2: Sales Forecast and Target Price - Morgan Stanley predicts that by 2027, Innovent will have over ten products on the market, with sales potentially reaching 17 billion RMB [1] - A target price of 110 HKD is set for Innovent Biologics [1] Group 3: Stock Performance and Investor Sentiment - On October 8, Innovent Biologics' stock price fell by approximately 7%, compared to a 1.5% decline in the Hang Seng Healthcare Index (HSHCI) on the same day [1] - Investor concerns are linked to the recent announcement regarding the national medical insurance drug directory negotiations, particularly regarding the impact of Eli Lilly's Tirzepatide on the sales potential of Innovent's Mazdutide [1] - There are also worries that Innovent may need to implement greater-than-expected price reductions to include small molecule inhibitors in the medical insurance directory [1]